Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 7/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.36 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23404650 | 1.00 | ITGB1 (0.39) | ITGB1ITGA4CTSAKCNK3USP9X | |
| SCHEMBL23404646 | 1.00 | ITGB1 (0.39) | ITGB1ITGA4CTSAKCNK3USP9X | |
| SCHEMBL29511445 | 0.92 | ROCK2 (0.36) | CTSAKCNK3USP9XKCNK9 | |
| SCHEMBL24080932 | 0.92 | ROCK2 (0.36) | CTSAKCNK3USP9XKCNK9 | |
| SCHEMBL21271440 | 0.88 | CTSA (0.40) | CTSA | |
| SCHEMBL21271441 | 0.88 | CTSA (0.40) | CTSA | |
| SCHEMBL21271439 | 0.88 | CTSA (0.40) | CTSA | |
| SCHEMBL29511460 | 0.80 | RXFP1 (0.39) | CTSA | |
| SCHEMBL20154321 | 0.80 | RXFP1 (0.39) | CTSA | |
| SCHEMBL21314426 | 0.77 | ITGB1 (0.41) | ITGB1ITGA4KCNK3USP9X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| CN-111433207-A | As αVPyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2020-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGB5 | ITGB1 1/4885ITGA4 11/4885CTSA 2376/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | ITGB1 1/4885ITGA4 9/4885CTSA 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.